Fellowship Award Winners
2025 Call No 6:
- Annaise Jauch, Uni Basel: “Advancing ITP Treatment: Exploring Eltrombopag and Immune Biomarkers for Personalized Therapy ”
- Emanuel Rom, Uni Zürich: "Inflammasome Inhibition in Acute Myeloid Leukemia"
2024: Call No 5:
- Maxime Zermatten, CHUV: "Usefulness of global hemostatic tests in the identification of patients with multiple myeloma at high thrombotic risk - The ThroMMbosis Study"
2023: Call No 4:
- Kevin Hofer, Uni Zürich: "Prevalence and clinical course of occult bacterial infections after B-cell depletion therapies"
2022: Call No 3:
- Nastassja K. Scheidegger, Dana-Farber Cancer Institute (USA), “Genome-scale CRISPR/Cas9 screen to identify new therapeutic strategies with exportin 1 inhibitors in acute myeloid leukemia harboring NPM l mutations”
- Roman Schimmer, Uni Zürich: “Development of pre-clinical acute myeloid leukemia (AML) models through combinatorial CRISPR/Cas9-mediated genome editing”: Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells | EMBO Molecular Medicine
2021: Call No 2:
- Adalgisa Condoluci, Institute of Oncology Research, Bellinzona: “Reprogramming the spenic marginal zone lymphoma-educated micrienvironment to RESTORE immune surveillance”
2020: Call No 1:
- Katarzyna Aleksandra Jalowiec, Inselspital Bern: “Molecular Analysis in Patients with Idiopathic Erythrocytosis”
- Sebastian Stolz, Uni Zürich: The mechanisms of chemotherapy-induced clonal expansion in TP53-mutated premalignant blood cells"
Research Grant Winners
2025: Call No 6:
- Davide Rossi, Universita della Svizzera Italiana: “Analyzing the Effect of Non-Coding Mutations in the Regulatory Region of CD83 in Lymphomas”
- Katarzyna Jalowiec, Uni Bern: "Taking a deeper look at PIEZO1 gene in RBCs and its clinical impact: PIEZO1 mutations in erythrocytosis and “Er” blood group antigens"
- Kristina Vrotniakaite, Ottawa Health Research Institute: “Development of risk stratification scores for recurrent venous thromboembolism and treatment-related clinically relevant bleeding in patients with cancer-associated thrombosis. (CAN-CATCH study)”.
2024: Call No 5:
- Stefanie Kreutmair, University of Zurich: “Distinct Immune lndscapes in NPM1C acute amyloid leukemia”
- Jürg Schwaller, Department of Biomedicine University of Basel: "Lineage-biased stem cells in JAK2-driven myeloproliferative neoplasms (MPN)"
- Böttcher Steffen, University Hospital Zurich: “From clonal hematopoiesis to therapy - related myeloid neoplasms”
2023: Call No 4:
- Linet Njue, University of Bern (Inselspital): “Gas6/Axl analysis in patients with sickle-cell anemia”
- Alicia Rovó, University of Bern (Inselspital): “Clinical and functional investigation of novel molecules involved in bone marrow fibrosis in MPN”
2022: Call No 3:
- Markus Schmugge, University Children’s Hospital Zurich: “Molekular crosstalk mechanisms between apoptosis and autophagy in platelets and megakaryocytes in immune thrombocytopenia”; (Schmugge et al B J Haematol 2023 und Editorial durch Kapur und Stein et al VTH Blood 2024, in press)
2021: Call No 2:
- Davide Rossi, Institute of Oncology Research, Bellinzona: “Adaption of chronic lymphatic leukemia to BTK inhibitors is mediated by by-pass signaling via MAPK pathway: implications for targeting minimal residual disease”
- Böttcher Steffen, University Hospital Zurich: “From clonal hematopoiesis to therapy - related myeloid neoplasms”
2020: Call No 1:
- Lorenzo Alberio, CHUV, “BioCAP - Platelet biotinylation for in vivo functional analysis in humans”
- Alexander Pierre André Theocharides, University Hospital Zurich: "The role of protein degradation pathways in calreticulin mutated myeloproliferative neoplasms"